Join Dr. Yuki Kato Maves, PhD at Phacilitate Advanced Therapy Week for her presentation during the Future of Apheresis & Collection Session. Date: January 23rd, 10:00-11:00 AM CT Location: Theater 5 (Supply Track) Learn about the importance of apheresis and donor selection within the current allogeneic cell and gene therapy landscape and how emerging trends and innovative strategies are addressing ongoing challenges.
Discovery Life Sciences’ Post
More Relevant Posts
-
Tiny tools for big breakthroughs! Bio-Rad Laboratories’s VeriCheck ddPCR Kits are here to supercharge AAV gene therapy research with precise, reliable results. Why settle for "meh" accuracy when you can have ddPCR precision? These kits simplify workflows while giving you the data confidence to go from "What if?" to "Look what we did!" Ready to expand your AAV research horizons? Check out the details: https://bit.ly/4jC2MbV
-
-
At the last CryoChats™, panelists discussed issues and challenges on the clinical aspects of cell therapy. Listen to Kevin Land MD of Vitalant discuss his observations in this clip for the topic: 'The Last 100 Yards: Cell and Gene Therapy Clinical Considerations'. 💡 Don’t miss out on the next CryoChats™! February 26th at 2PM ET – Topic to be Determined ❄ Register Here: https://lnkd.in/gUXVHa83 #Cryopreservation #Biotechnology #ResearchAndDevelopment #CellTherapy #EviaBio #LifeScience
-
This paper presents an improved anion exchange analytical method . It delivers enhanced separation of full AAV capsids from other common product-related impurities such as aggregates, and empty, partially filled, high density, or damaged capsids. The improved anion exchange analytical method has been shown to be applicable for different AAV serotypes.
The improved AEX analytical method delivers enhanced separation of not only empty and full AAV capsids, but also other impurities, such as partially filled and heavy capsids, and aggregates. Just published in: Cell & Gene Therapy Insights 2024; 10(3), 503–511 DOI: 10.18609/cgti.2024.063
-
-
Leveraging the world's genomic data to tackle historically undruggable small molecule drug targets
I'm thrilled to announce that Rgenta has received funding from the Friedreich's Ataxia Research Alliance! Our team is dedicated to using our RSwitch technology to create a transformative gene therapy for FA. Because carefully balanced frataxin (FXN) levels are essential for successful FA treatment, our technology, developed by Sam Hasson and the team, offers a promising solution to this critical challenge.
The FARA Grant Program is proud to award a General Research Grant to Samuel Hasson, PhD, of Rgenta Therapeutics Inc., to develop a way to finely tune frataxin levels in gene therapy approaches for #FriedreichAtaxia (FA). Learn more about this grant and other FARA-funded research at https://buff.ly/4haecBZ.
-
-
Honored to be working with Friedreich's Ataxia Research Alliance (FARA) to apply Rgenta's proprietary RSwitch technology to solve a major challenge for groups developing gene replacement therapy for Friedreich's Ataxia and enable the potential for fine control of expression of the frataxin (FXN) transgene with an oral small molecule. RSwitch is an application of our technology developed to provide a new type of control mechanism; a "genetic dimmer switch" designed to make the levels of expression of a therapeutic gene dependent on the administration of an oral small molecule drug (RDrug). We believe that this novel switch has broad applicability in gene and cell-based therapies and are looking to partner with groups developing such therapies across a wide variety of therapeutic indications.
The FARA Grant Program is proud to award a General Research Grant to Samuel Hasson, PhD, of Rgenta Therapeutics Inc., to develop a way to finely tune frataxin levels in gene therapy approaches for #FriedreichAtaxia (FA). Learn more about this grant and other FARA-funded research at https://buff.ly/4haecBZ.
-
-
Design & execution of clinical trial operations & logistics globally | Supply Chain Management
Meet our Cerba Research experts at the upcoming ESGCT Conference. #cell&gene #clinicaltrial #esgct
We are thrilled to announce that Karthikeyan Devaraju will present at the ESGCT Conference, October 22 & 24. Make sure to attend our poster presentation speaking slots: Precision Mapping Viral Integration Landscapes with CRISPR-Cas9 and Long-Read Sequencing (Poster number P0513) Poster Session I on Tuesday, 22 October, from 19:30 to 21:00 Monitoring adenoviral gene therapy safety (Poster number P0981) Poster Session III on Thursday, 24 October, from 14:00 to 15:30 Learn more about our presence at ESGCT here: https://lnkd.in/eEJA2hXv #ESGCT #CellAndGeneTherapy #SpecialtyLab #CerbaResearch
-
-
Operationalizing #cellandgenetherapy trials is a significant and complex task that takes expert planning and implementation. Check out our webinar (https://lnkd.in/g87QdfCj) where Allucent experts Desmond Cabrera (VP, Project Management), Joyce Moore, PhD (Global Head, Patient Engagement), Francisca Samson - Graveland (Director, Data Management), and Marita Kruskopf Osterberg, PhD (Senior Manager, Study Start-Up) share insights and strategies on how to successfully conduct cell and gene therapy trials. #Allucent #BringNewTherapiesToLight #DrugDiscovery #ClinicalTrials #PatientEngagement #DrugDevelopment
-
-
We’re just TWO days away! 👥 Meet the experts behind our webinar. Join us July 25th at 2pm ET for "Navigating the Future of Cell and Gene Therapy: Financial Landscape & Market Dynamics by Disease Type." This is your last chance to register, don’t miss out on exclusive insights into market trends and investment opportunities. Register now! https://hubs.la/Q02HGTlg0 #CellandGeneTherapy #CGT #Kalorama #FinancialTrends #MarketDynamics #Webinar #RegisterNow
-
-
Using a phase-appropriate approach, our recombinant off-the-shelf AAV and LVV viral vectors and plasmids make for more simplified gene therapy development. Empower breakthroughs in your discovery phase and start with the end in mind with a complete concept to cure portfolio through Charles River. Empower Your Research: https://okt.to/KTzQ5e
-
Access article: https://lnkd.in/gg7jbyKj Discover the challenges and analytical tools for measuring potency at all stages of cell and gene therapy product development. Understand the unique challenges of measuring expression, activity, and safety from research lab to clinic. #genetherapy #lifesciences #research
